Anti-PD-1 combined with hypomethylating agent and CAG regimen bridging to allogeneic hematopoietic stem cell transplantation: a novel strategy for relapsed/refractory acute myeloid leukemia
The anti-PD-1+HMA+CAG regimen bridging to allo-HSCT for r/r AML was tolerable with promising efficacy. GVHD prophylaxis with PTCy for HID-HSCT showed preliminary survival advantage.
Authors
- Dai‐Hong Liu (ORCID: https://orcid.org/0000-0003-3334-9113)
- Xiaoning Gao (ORCID: https://orcid.org/0000-0003-2035-7472)
- An Wang (ORCID: https://orcid.org/0000-0002-7027-6614)
- Yuxin Wang (ORCID: https://orcid.org/0000-0002-5810-8968)
- Yuhang Li (ORCID: https://orcid.org/0000-0003-4086-0323)
- Jun Wang (ORCID: https://orcid.org/0000-0002-5992-1862)
- Jing Yu (ORCID: https://orcid.org/0000-0002-8694-8948)
- Xuan Zheng (ORCID: https://orcid.org/0000-0002-8433-6198)
- Lei Xu (ORCID: https://orcid.org/0000-0002-3573-8334)
- Yizhi Wang (ORCID: https://orcid.org/0009-0008-1449-8424)
- Yong-Feng Su
- Chunji Gao
- Fei Li (ORCID: https://orcid.org/0000-0001-6211-6306)
- Liangding Hu
Institutions
- Chinese PLA General Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-08-16
- DOI
- https://doi.org/10.3389/fimmu.2024.1409302
- Citations
- 4
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- National Natural Science Foundation of China